BioDelivery Sciences International Stock Price, News & Analysis (NASDAQ:BDSI)

$2.70 0.12 (4.65 %)
(As of 01/22/2018 09:19 AM ET)
Previous Close$2.58
Today's Range$2.53 - $2.70
52-Week Range$1.55 - $3.60
Volume532,970 shs
Average Volume613,538 shs
Market Capitalization$150.89 million
P/E Ratio30.00
Dividend YieldN/A
Beta0.74

About BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International logoBioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company's products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive BDSI News and Ratings via Email

Sign-up to receive the latest news and ratings for BDSI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorHealthcare
SymbolNASDAQ:BDSI
CUSIP09060J10
Phone+1-919-5829050

Debt

Debt-to-Equity Ratio1.89%
Current Ratio1.28%
Quick Ratio1.07%

Price-To-Earnings

Trailing P/E Ratio30
Forward P/E Ratio16.88
P/E GrowthN/A

Sales & Book Value

Annual Sales$15.55 million
Price / Sales9.70
Cash FlowN/A
Price / CashN/A
Book Value($0.33) per share
Price / Book-8.18

Profitability

Trailing EPS$0.09
Net Income$-67,130,000.00
Net Margins10.40%
Return on Equity33.83%
Return on Assets6.43%

Miscellaneous

Employees99
Outstanding Shares55,880,000

BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions

What is BioDelivery Sciences International's stock symbol?

BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."

How were BioDelivery Sciences International's earnings last quarter?

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its quarterly earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The specialty pharmaceutical company had revenue of $11.25 million for the quarter, compared to analysts' expectations of $9.40 million. BioDelivery Sciences International had a net margin of 10.40% and a return on equity of 33.83%. The business's quarterly revenue was up 215.1% compared to the same quarter last year. During the same period last year, the firm posted ($0.30) earnings per share. View BioDelivery Sciences International's Earnings History.

When will BioDelivery Sciences International make its next earnings announcement?

BioDelivery Sciences International is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for BioDelivery Sciences International.

Where is BioDelivery Sciences International's stock going? Where will BioDelivery Sciences International's stock price be in 2018?

6 analysts have issued 1-year price objectives for BioDelivery Sciences International's stock. Their predictions range from $4.00 to $5.00. On average, they expect BioDelivery Sciences International's stock price to reach $4.50 in the next twelve months. View Analyst Ratings for BioDelivery Sciences International.

What are Wall Street analysts saying about BioDelivery Sciences International stock?

Here are some recent quotes from research analysts about BioDelivery Sciences International stock:

  • 1. According to Zacks Investment Research, "BioDelivery’s has secured improved positioning in six new managed care contracts providing preferred access to its key drug Bunavail since July last year, which is expected to boost the drug’s sales and profitability in 2017. Moreover, its second marketed drug Belbuca’s sales hit all-time high since the product was launched a year ago. However, the company recently discontinued development of clonidine topical gel for management of painful diabetic neuropathy. BioDelivery’s portfolio as well as its pipeline candidates may also face sever competition as it targets a highly genericized and crowded market. Its share significantly outperformed the Zacks classified Medical-Biomed/Genetics market so far this year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (7/17/2017)
  • 2. Cantor Fitzgerald analysts commented, "A Lot of Moving Parts and 1x Items: BDSI reported 1Q17 results posting net income of $0.89, the majority of which was attributed to positive effects of the Belbuca return. These items included $20M in deferred revenue recognition, $27M in non-cash bargain purchase gain and a $16M tax benefit. Without these additions, BDSI would have reported a loss of ($0.23). BDSI finished 1Q with $35.2M in cash, which the company estimates should fund operations into 2H18. We have adjusted our estimates to reflect quarter and year end results. Alignment of Fundamentals: We have watched the re-launch of Belbuca closely following the ENDP transition with the recently expanded sales force growing Rx numbers through 1Q and April, per Symphony data. More importantly, $/Rx continues to increase with due to larger prescriptions and incremental price increases. We also note a significant shift to commercial payor which should allow for increased gross/net adding to the top-line. The expanded sales force of 65 armed with revised marketing messaging, particularly around titration, has been targeting physicians familiar with the buprenorphine molecule with success, in our view. We believe additional education campaigns such as speaker programs and a PAINWeekEND symposium will drive interest. Additional Upside: We see additional upside as BDSI focuses on managed Medicaid contracts of which BDSI as of Feb." (5/16/2017)
  • 3. FBR & Co analysts commented, "BioDelivery reported 4Q16 results after the close on March 16. On the morning of March 17, management hosted a call to provide an update on 2017 progress. The company recently announced that it has entered into a senior credit facility with affiliates of CRG LP , which is a healthcare-focused investment firm, and currently has debt financing of up to $75M secured, with initial proceeds extending the company’s cash runway into 2H18." (3/20/2017)

Who are some of BioDelivery Sciences International's key competitors?

Who are BioDelivery Sciences International's key executives?

BioDelivery Sciences International's management team includes the folowing people:

  • Frank E. O'Donnell Jr., M.D., Executive Chairman of the Board (Age 66)
  • Scott Plesha, President
  • Ernest R. De Paolantonio CPA, Chief Financial Officer, Treasurer, Secretary (Age 63)
  • Niraj Vasisht Ph.D., Senior Vice President, Chief Technology Officer (Age 52)
  • Peter L. Ginsberg, Vice President - Business Development
  • William B. Stone, Lead Independent Director (Age 73)
  • Timothy C. Tyson, Director (Age 62)
  • Charles J. Bramlage, Independent Director (Age 55)
  • Thomas W. D'Alonzo, Independent Director (Age 72)
  • Barry I. Feinberg M.D., Independent Director (Age 60)

How do I buy BioDelivery Sciences International stock?

Shares of BioDelivery Sciences International can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioDelivery Sciences International's stock price today?

One share of BioDelivery Sciences International stock can currently be purchased for approximately $2.70.

How big of a company is BioDelivery Sciences International?

BioDelivery Sciences International has a market capitalization of $150.89 million and generates $15.55 million in revenue each year. The specialty pharmaceutical company earns $-67,130,000.00 in net income (profit) each year or $0.09 on an earnings per share basis. BioDelivery Sciences International employs 99 workers across the globe.

How can I contact BioDelivery Sciences International?

BioDelivery Sciences International's mailing address is 4131 Parklake Ave Ste 225, RALEIGH, NC 27612-2390, United States. The specialty pharmaceutical company can be reached via phone at +1-919-5829050 or via email at [email protected]


MarketBeat Community Rating for BioDelivery Sciences International (BDSI)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  307 (Vote Outperform)
Underperform Votes:  150 (Vote Underperform)
Total Votes:  457
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioDelivery Sciences International (NASDAQ:BDSI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.832.832.50
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.50$4.50$4.50$4.17
Price Target Upside: 91.49% upside91.49% upside52.54% upside28.21% upside

BioDelivery Sciences International (NASDAQ:BDSI) Consensus Price Target History

Price Target History for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ:BDSI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/27/2017HC WainwrightSet Price TargetBuy$5.00HighView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$5.00N/AView Rating Details
10/22/2017Piper Jaffray CompaniesSet Price TargetBuy$4.00N/AView Rating Details
10/12/2017Cantor FitzgeraldSet Price TargetBuy$5.00N/AView Rating Details
7/24/2017Janney Montgomery ScottBoost Price TargetBuy -> Fair Value$3.00 -> $4.00HighView Rating Details
5/16/2017FBR & CoSet Price TargetBuy$4.00MediumView Rating Details
3/14/2016LaidlawLower Price TargetBuy$17.00 -> $11.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

BioDelivery Sciences International (NASDAQ:BDSI) Earnings History and Estimates Chart

Earnings by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ BDSI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018($0.24)N/AView Earnings Details
11/9/2017Q3 2017($0.22)($0.21)$9.40 million$11.25 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.23)($0.27)$8.45 million$8.70 millionViewListenView Earnings Details
5/15/2017Q1 2017$0.09$0.58$27.07 million$29.48 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.26)($0.29)$6.37 million$3.90 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.30)$3.58 million$3.60 millionViewListenView Earnings Details
8/9/2016Q216($0.31)($0.31)$3.35 million$5.00 millionViewN/AView Earnings Details
5/10/2016Q116($0.35)($0.36)$2.96 million$3.00 millionViewListenView Earnings Details
3/10/2016Q415$0.55$0.19$52.40 million$32.20 millionViewListenView Earnings Details
11/9/2015Q315($0.34)($0.39)$1.56 million$1.20 millionViewN/AView Earnings Details
8/10/2015Q215($0.31)($0.37)$3.29 million$1.70 millionViewListenView Earnings Details
5/11/2015Q115($0.20)($0.16)$10.80 million$13.10 millionViewListenView Earnings Details
3/16/2015Q414($0.40)($0.51)$4.00 million$2.50 millionViewN/AView Earnings Details
11/5/2014Q3 2014($0.29)($0.39)$3.02 million$1.82 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.07)($0.14)$11.65 million$13.89 millionViewN/AView Earnings Details
5/9/2014Q114($0.15)($0.11)$11.60 million$20.69 millionViewN/AView Earnings Details
3/14/2014($0.22)($0.33)ViewN/AView Earnings Details
11/12/2013Q3 2013($0.32)($0.49)ViewN/AView Earnings Details
8/9/2013Q2 2013($0.34)($0.35)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.42)($0.36)ViewN/AView Earnings Details
3/18/2013Q4 2012($0.18)$0.09ViewN/AView Earnings Details
11/8/2012Q3 2012($0.32)($0.64)ViewN/AView Earnings Details
8/9/2012Q2 2012$0.27$0.08ViewN/AView Earnings Details
5/10/2012Q1 2012$0.64$0.75ViewN/AView Earnings Details
3/19/2012Q4 2011($0.21)($0.16)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.21)($0.17)ViewN/AView Earnings Details
5/13/2011Q1 2011($0.25)($0.34)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BioDelivery Sciences International (NASDAQ:BDSI) Earnings Estimates

Current Year EPS Consensus Estimate: $0.16 EPS
Next Year EPS Consensus Estimate: $-0.7 EPS

Dividends

Dividend History for BioDelivery Sciences International (NASDAQ:BDSI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioDelivery Sciences International (NASDAQ BDSI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.73%
Institutional Ownership Percentage: 44.25%
Insider Trades by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)
Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

BioDelivery Sciences International (NASDAQ BDSI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/19/2018Mark A SirgoDirectorSell709,502$2.73$1,936,940.461,759,262View SEC Filing  
1/17/2018Mark A SirgoDirectorSell108,000$2.57$277,560.001,759,262View SEC Filing  
1/3/2018Mark A SirgoDirectorSell162,509$2.78$451,775.021,759,262View SEC Filing  
9/21/2017Mark A SirgoInsiderSell201,373$2.84$571,899.321,509,262View SEC Filing  
9/20/2017Mark A SirgoCEOSell65,405$2.75$179,863.751,509,262View SEC Filing  
9/19/2017Mark A SirgoCEOSell24,516$2.75$67,419.001,509,262View SEC Filing  
9/18/2017Mark A SirgoCEOSell6,000$2.85$17,100.001,509,262View SEC Filing  
9/15/2017Mark A SirgoCEOSell54,833$2.90$159,015.701,509,262View SEC Filing  
9/14/2017Mark A SirgoCEOSell50,000$2.95$147,500.001,509,262View SEC Filing  
3/31/2017Mark A SirgoCEOSell110,895$1.90$210,700.501,670,157View SEC Filing  
3/23/2017Francis E Odonnell JrDirectorSell750$1.90$1,425.00272,049View SEC Filing  
3/23/2017Niraj VasishtSVPSell530$1.90$1,007.00272,943View SEC Filing  
3/23/2017Paolantonio Ernest Robert DeCFOSell170$1.90$323.0096,634View SEC Filing  
1/30/2017Niraj VasishtInsiderSell6,905$1.91$13,188.55178,727View SEC Filing  
12/1/2016Samuel P. Sears, Jr.DirectorSell12,000$1.67$20,040.00View SEC Filing  
11/23/2016Barry I FeinbergDirectorBuy2,000$1.67$3,340.00View SEC Filing  
11/17/2016Barry I FeinbergDirectorBuy3,000$1.87$5,610.00View SEC Filing  
9/23/2016Francis E Odonnell JrDirectorSell100,000$2.57$257,000.00View SEC Filing  
9/23/2016Niraj VasishtInsiderSell47,000$2.43$114,210.0073,081View SEC Filing  
9/22/2016Paolantonio Ernest Robert DeCFOSell14,800$2.44$36,112.0014,866View SEC Filing  
8/25/2016Barry I FeinbergDirectorBuy2,500$2.55$6,375.00View SEC Filing  
8/11/2016William B StoneDirectorSell16,000$2.57$41,120.00122,675View SEC Filing  
3/21/2016Charles BramlageDirectorBuy8,850$2.82$24,957.0028,150View SEC Filing  
3/18/2016Barry I FeinbergDirectorBuy10,000$2.74$27,400.00View SEC Filing  
3/18/2016Niraj VasishtCTOBuy1,000$2.80$2,800.0068,420View SEC Filing  
3/17/2016Paolantonio Ernest Robert DeCFOBuy4,000$2.60$10,400.0013,383View SEC Filing  
11/24/2015Francis E Odonnell JrDirectorSell50,000$6.01$300,500.00View SEC Filing  
11/13/2015Thomas D'alonzoDirectorBuy4,528$5.52$24,994.5676,379View SEC Filing  
9/3/2015Francis E Odonnell JrDirectorSell20,000$6.43$128,600.00144,671View SEC Filing  
8/26/2015Paolantonio Ernest Robert DeCFOBuy1,650$6.20$10,230.009,383View SEC Filing  
8/13/2015William B StoneDirectorSell11,500$7.01$80,615.00View SEC Filing  
6/16/2015Francis E Odonnell JrDirectorSell21,597$8.03$173,423.91View SEC Filing  
6/16/2015Mark A SirgoCEOSell4,187$7.97$33,370.39View SEC Filing  
5/26/2015Barry I FeinbergDirectorBuy2,000$7.84$15,680.00View SEC Filing  
5/14/2015Barry I FeinbergDirectorBuy2,000$8.54$17,080.00View SEC Filing  
5/13/2015Thomas D'alonzoDirectorBuy6,226$8.07$50,243.82View SEC Filing  
12/26/2014Francis E Odonnell JrDirectorSell70,000$12.00$840,000.00View SEC Filing  
12/15/2014Mark A SirgoCEOBuy2,500$12.23$30,575.00View SEC Filing  
12/10/2014Samuel P Sears JrDirectorSell7,853$15.03$118,030.59View SEC Filing  
11/12/2014William B StoneDirectorSell14,000$16.11$225,540.00View SEC Filing  
9/4/2014Barry I FeinbergDirectorBuy1,000$15.18$15,180.00View SEC Filing  
9/4/2014Mark A SirgoCEOBuy2,000$15.04$30,080.00View SEC Filing  
8/27/2014Andrew L FinnEVPSell90,000$15.00$1,350,000.00View SEC Filing  
8/22/2014Charles BramlageDirectorBuy1,800$13.85$24,930.00View SEC Filing  
6/25/2014Paolantonio Ernest Robert DeCFOBuy1,250$12.13$15,162.50View SEC Filing  
6/12/2014Samuel P Sears JrDirectorSell5,000$12.33$61,650.00View SEC Filing  
6/11/2014Francis E Odonnell JrDirectorSell125,000$11.04$1,380,000.00View SEC Filing  
3/26/2014Francis Odonnell, Jr.DirectorSell50,000$8.04$402,000.00View SEC Filing  
3/20/2014Samuel Sears, Jr.DirectorSell4,000$9.00$36,000.0019,853View SEC Filing  
3/11/2014Andrew FinnEVPSell80,000$9.99$799,200.00660,450View SEC Filing  
3/11/2014William StoneDirectorSell35,000$10.00$350,000.0063,178View SEC Filing  
2/20/2014Andrew FinnEVPSell18,737$8.84$165,635.08740,450View SEC Filing  
2/20/2014Francis Odonnell, Jr.DirectorSell70,000$8.92$624,400.002,521,751View SEC Filing  
2/20/2014Mark SirgoCEOSell42,000$8.92$374,640.00913,250View SEC Filing  
1/24/2014Andrew FinnEVPSell143,679$9.03$1,297,421.37705,653View SEC Filing  
1/24/2014James McnultySVPSell89,223$8.73$778,916.7949,399View SEC Filing  
1/24/2014John SheaDirectorSell130,000$8.78$1,141,400.0013,305View SEC Filing  
1/24/2014Mark SirgoCEOSell116,253$9.01$1,047,439.53815,250View SEC Filing  
11/18/2013Mark SirgoCEOBuy2,337$4.29$10,025.73874,179View SEC Filing  
9/19/2013Francis Odonnell, Jr.DirectorSell95,000$5.36$509,200.003,121,751View SEC Filing  
9/11/2013Samuel P Sears JrDirectorSell2,000$5.37$10,740.00View SEC Filing  
9/9/2013Samuel P Sears JrDirectorSell7,500$5.05$37,875.00View SEC Filing  
8/26/2013Andrew FinnEVPBuy5,000$4.58$22,900.00775,653View SEC Filing  
8/16/2013Mark SirgoCEOBuy5,100$4.43$22,593.00871,842View SEC Filing  
8/15/2013William StoneDirectorSell6,825$4.44$30,303.0063,175View SEC Filing  
8/14/2013James McnultyCFOBuy5,000$4.50$22,500.0049,399View SEC Filing  
6/21/2013Mark A SirgoCEOBuy3,400$4.30$14,620.00View SEC Filing  
6/20/2013Francis E Odonnell JrDirectorSell72,689$4.36$316,924.04View SEC Filing  
6/5/2013Samuel P Sears JrDirectorSell5,000$4.42$22,100.00View SEC Filing  
12/21/2012Andrew L FinnEVPBuy3,000$3.85$11,550.00View SEC Filing  
12/21/2012Mark A SirgoCEOBuy4,975$4.02$19,999.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioDelivery Sciences International (NASDAQ BDSI) News Headlines

Source:
DateHeadline
Insider Selling: BioDelivery Sciences International, Inc. (BDSI) Director Sells 108,000 Shares of StockInsider Selling: BioDelivery Sciences International, Inc. (BDSI) Director Sells 108,000 Shares of Stock
www.americanbankingnews.com - January 19 at 9:52 PM
BioDelivery Sciences International, Inc. (BDSI) Director Sells $451,775.02 in StockBioDelivery Sciences International, Inc. (BDSI) Director Sells $451,775.02 in Stock
www.americanbankingnews.com - January 19 at 9:52 PM
BioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 709,502 SharesBioDelivery Sciences International, Inc. (BDSI) Director Mark A. Sirgo Sells 709,502 Shares
www.americanbankingnews.com - January 19 at 9:35 PM
Novartis (NVS) and BioDelivery Sciences International (BDSI) Head to Head ComparisonNovartis (NVS) and BioDelivery Sciences International (BDSI) Head to Head Comparison
www.americanbankingnews.com - January 15 at 3:10 PM
$9.91 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter$9.91 Million in Sales Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - January 9 at 5:58 AM
BioDelivery Sciences International, Inc. (BDSI) Expected to Post Earnings of -$0.23 Per ShareBioDelivery Sciences International, Inc. (BDSI) Expected to Post Earnings of -$0.23 Per Share
www.americanbankingnews.com - January 7 at 7:28 PM
BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018BioDelivery Sciences International, Inc. :BDSI-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
finance.yahoo.com - January 1 at 3:16 PM
BioDelivery Sciences International, Inc. (BDSI) Receives Consensus Rating of "Buy" from BrokeragesBioDelivery Sciences International, Inc. (BDSI) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 29 at 8:04 AM
BDSI’s new president: Were expanding our sales forceBDSI’s new president: We're expanding our sales force
finance.yahoo.com - December 22 at 3:15 PM
 Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per Share Brokerages Anticipate BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - December 22 at 11:26 AM
BioDelivery Sciences (BDSI) Names Scott Plesha as President - StreetInsider.comBioDelivery Sciences (BDSI) Names Scott Plesha as President - StreetInsider.com
www.streetinsider.com - December 21 at 5:32 AM
BDSI names new presidentBDSI names new president
www.bizjournals.com - December 20 at 3:15 PM
BioDelivery Sciences (BDSI) Names Scott Plesha as PresidentBioDelivery Sciences (BDSI) Names Scott Plesha as President
www.streetinsider.com - December 20 at 3:15 PM
BioDelivery Sciences (BDSI) Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA ... - StreetInsider.comBioDelivery Sciences (BDSI) Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA ... - StreetInsider.com
www.streetinsider.com - December 19 at 5:31 AM
BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032 - GlobeNewswire (press release)BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032 - GlobeNewswire (press release)
globenewswire.com - December 19 at 5:31 AM
BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032
finance.yahoo.com - December 18 at 3:15 PM
BioDelivery Sciences Reacquires ONSOLIS® from Collegium ... - GlobeNewswire (press release)BioDelivery Sciences Reacquires ONSOLIS® from Collegium ... - GlobeNewswire (press release)
globenewswire.com - December 15 at 5:33 AM
BioDelivery Sciences International, Inc. (BDSI) Short Interest Up 32.5% in NovemberBioDelivery Sciences International, Inc. (BDSI) Short Interest Up 32.5% in November
www.americanbankingnews.com - December 15 at 3:08 AM
Adamis Pharmaceuticals (ADMP) versus BioDelivery Sciences International (BDSI) Critical AnalysisAdamis Pharmaceuticals (ADMP) versus BioDelivery Sciences International (BDSI) Critical Analysis
www.americanbankingnews.com - December 11 at 1:26 AM
-$0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter-$0.23 EPS Expected for BioDelivery Sciences International, Inc. (BDSI) This Quarter
www.americanbankingnews.com - December 4 at 3:14 PM
Financial Comparison: BioDelivery Sciences International (BDSI) and Patheon (PTHN)Financial Comparison: BioDelivery Sciences International (BDSI) and Patheon (PTHN)
www.americanbankingnews.com - December 4 at 9:10 AM
BDSI CEO on big formulary addBDSI CEO on big formulary add
www.bizjournals.com - November 30 at 3:16 PM
Comparing SciClone Pharmaceuticals (SCLN) & BioDelivery Sciences International (BDSI)Comparing SciClone Pharmaceuticals (SCLN) & BioDelivery Sciences International (BDSI)
www.americanbankingnews.com - November 30 at 3:12 AM
BRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To FormularyBRIEF-BioDelivery Sciences Says ‍Ohio Workers Compensation Approved Change To Formulary
www.reuters.com - November 27 at 5:48 PM
BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to FormularyBioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary
finance.yahoo.com - November 27 at 5:48 PM
BioDelivery Sciences International, Inc. (BDSI) PT Set at $5.00 by HC WainwrightBioDelivery Sciences International, Inc. (BDSI) PT Set at $5.00 by HC Wainwright
www.americanbankingnews.com - November 27 at 1:56 PM
Roth Capital Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price TargetRoth Capital Analysts Give BioDelivery Sciences International, Inc. (BDSI) a $5.00 Price Target
www.americanbankingnews.com - November 25 at 5:28 PM
BioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.80 MillionBioDelivery Sciences International, Inc. (BDSI) Expected to Post Quarterly Sales of $9.80 Million
www.americanbankingnews.com - November 18 at 9:00 AM
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray ... - PR Newswire (press release)BioDelivery Sciences to Present at the 29th Annual Piper Jaffray ... - PR Newswire (press release)
www.prnewswire.com - November 16 at 11:52 AM
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray ConferenceBioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
finance.yahoo.com - November 16 at 11:52 AM
Zacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per ShareZacks: Brokerages Expect BioDelivery Sciences International, Inc. (BDSI) Will Announce Earnings of -$0.23 Per Share
www.americanbankingnews.com - November 16 at 3:10 AM
Cantor Fitzgerald Analysts Lower Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)Cantor Fitzgerald Analysts Lower Earnings Estimates for BioDelivery Sciences International, Inc. (BDSI)
www.americanbankingnews.com - November 15 at 1:40 PM
BioDelivery Sciences International, Inc. Forecasted to Earn FY2017 Earnings of $0.15 Per Share (BDSI)BioDelivery Sciences International, Inc. Forecasted to Earn FY2017 Earnings of $0.15 Per Share (BDSI)
www.americanbankingnews.com - November 14 at 9:04 AM
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update - PR Newswire (press release)
www.prnewswire.com - November 10 at 1:09 PM
BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates - NasdaqBioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates - Nasdaq
www.nasdaq.com - November 10 at 1:09 PM
Edited Transcript of BDSI earnings conference call or presentation 9-Nov-17 9:30pm GMTEdited Transcript of BDSI earnings conference call or presentation 9-Nov-17 9:30pm GMT
finance.yahoo.com - November 10 at 1:09 PM
BioDelivery Sciences International, Inc. (BDSI) Announces  Earnings ResultsBioDelivery Sciences International, Inc. (BDSI) Announces Earnings Results
www.americanbankingnews.com - November 10 at 12:51 PM
Investor Network: BioDelivery Sciences International, Inc. to Host Earnings CallInvestor Network: BioDelivery Sciences International, Inc. to Host Earnings Call
www.finanznachrichten.de - November 9 at 5:34 PM
BioDelivery Sciences International, Inc. 2017 Q3 - Results - Earnings Call SlidesBioDelivery Sciences International, Inc. 2017 Q3 - Results - Earnings Call Slides
seekingalpha.com - November 9 at 5:34 PM
BioDelivery Sciences International, Inc. to Host Earnings CallBioDelivery Sciences International, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 5:34 PM
Is BioDelivery Sciences International Inc’s (BDSI) Balance Sheet Strong Enough To Weather A Storm?Is BioDelivery Sciences International Inc’s (BDSI) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 9 at 5:34 PM
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateBioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 9 at 5:34 PM
BioDelivery reports 3Q lossBioDelivery reports 3Q loss
finance.yahoo.com - November 9 at 5:33 PM
BioDelivery Sciences International, Inc. (BDSI) Given Average Recommendation of "Buy" by BrokeragesBioDelivery Sciences International, Inc. (BDSI) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 9 at 8:30 AM
BioDelivery (BDSI) to Report Q3 Earnings: Whats in Store?BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
www.zacks.com - November 7 at 11:52 PM
BioDelivery (BDSI) to Report Q3 Earnings: Whats in Store? - NasdaqBioDelivery (BDSI) to Report Q3 Earnings: What's in Store? - Nasdaq
www.nasdaq.com - November 7 at 6:52 PM
BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?
finance.yahoo.com - November 7 at 6:51 PM
Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences ... - PR Newswire (press release)Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences ... - PR Newswire (press release)
www.prnewswire.com - November 4 at 3:05 AM
Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI)Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
finance.yahoo.com - November 3 at 10:04 PM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.
finance.yahoo.com - November 2 at 5:05 PM

SEC Filings

BioDelivery Sciences International (NASDAQ:BDSI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioDelivery Sciences International (NASDAQ:BDSI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioDelivery Sciences International (NASDAQ BDSI) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.